The importance of pharmacogenetic tests in evaluation of the effectiveness of methotrexate treatment in rheumatoid arthritis (part 1);Znaczenie badán farmakogenetycznych w efektywności leczenia metotreksatem chorych na reumatoidalne zapalenie stawów (Czȩść 1)

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 65, Issue , 2011, Pages 195-206

  Świerkot, Jerzy ^a   Ślȩzak, Ryszard ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Methotrexate; Polymorphism; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER; METHOTREXATE;

ARTICLE; GENETIC POLYMORPHISM; HUMAN; PHARMACOGENETICS; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; HUMANS; METHOTREXATE; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 79958774140     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: 10.5604/17322693.936689     Document Type: Review

References (70)

1. Berkun Y., Levartovsky D., Rubinow A., Orbach H., Aamar S., Grenader T., Abou Atta I., Mevorach D., Friedman G., Ben-Yehuda A.: Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene. Ann. Rheum. Dis., 2004; 63: 1227-1231. (Pubitemid 39273498)
2. Bohanec Grabar P., Logar D., Lestan B., Dolzan V.: Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism. Eur. J. Clin. Pharmacol., 2008; 64: 1057-1068.
3. Brzezińska A., Wińska P., Balińska M.: Cellular aspects of folate and antifolate membrane transport. Acta Biochim. Pol., 2000; 47: 735-749.
4. Campalani E., Arenas M., Marinaki A.M., Lewis C.M., Barker J.N., Smith C.H.: Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis. Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis. J. Invest. Dermatol., 2007; 127: 1860-1867.
5. Cao H., Hegele R.A.: DNA polymorphisms in ITPA including basis of inosine triphosphatase deficiency. J. Hum. Genet., 2002; 47: 620-622. (Pubitemid 36083264)
6. Chango A., Emery-Fillon N., de Courcy G.P., Lambert D., Pfister M., Rosenblatt D.S., Nicolas J.P.: A polymorphism (80G->A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Mol. Genet. Metab., 2000; 70: 310-315.
7. Chave K.J., Ryan T.J., Chmura S.E., Galivan J.: Identification of single nucleotide polymorphisms in the human gamma-glutamyl hydrolase gene and characterization of promoter polymorphisms. Gene, 2003; 13: 167-175. (Pubitemid 37346211)
8. Chen Z., Karaplis A.C., Ackerman S.L., Pogribny I.P., Melnyk S., Lussier-Cacan S., Chen M.F., Pai A., John S.W., Smith R.S., Bottiglieri T., Bagley P., Selhub J., Rudnicki M.A., James S.J., Rozen R.: Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition. Hum. Mol. Genet., 2001; 10: 433-443. (Pubitemid 32181666)
9. Chen Z.S., Lee K., Walther S.: Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res., 2002; 62: 3144-3150. (Pubitemid 34602407)
10. Cheng Q., Cheng C., Crews K.R., Ribeiro R.C., Pui C.H., Relling M.V., Evans W.E.: Epigenetic regulation of human gamma-glutamyl hydrolase activity in acute lymphoblastic leukemia. Am. J. Hum. Genet., 2006; 79: 264-274. (Pubitemid 44141825)
11. Cheng Q., Wu B., Kager L., Panetta J.C., Zheng J., Pui C.H., Relling M.V., Evans W.E.: A substrate specific functional polymorphism of human gamma-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells. Pharmacogenetics, 2004; 14: 557-567. (Pubitemid 39100007)
12. Ciechanowicz A., Kokot F.: Genetyka molekularna w chorobach wewnetrznych. Wydawnictwo Lekarskie PZWL, Warszawa 2008.
13. Cole P.D., Kamen B.A., Gorlick R., Banerjee D., Smith A.K., Magill E., Bertino J.R.: Effects of overexpression of gamma-glutamyl hydrolase on methotrexate metabolism and resistance. Cancer Res., 2001; 61: 4599-4604. (Pubitemid 32685795)
14. Cronstein B.N.: Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol. Rev., 2005; 57: 163-172. (Pubitemid 41043882)
15. Dervieux T., Furst D., Lein D.O.: Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study. Ann. Rheum. Dis., 2005; 64: 1180-1185. (Pubitemid 41113353)
16. Dervieux T., Furst D., Lein D.O., Capps R., Smith K., Walsh M., Kremer J.: Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum., 2004; 50: 2766-2774. (Pubitemid 39209513)
17. Dervieux T., Greenstein N., Kremer J.: Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum., 2006; 54: 3095-3103. (Pubitemid 44622078)
18. Dervieux T., Kremer J., Lein D.O., Capps R., Barham R., Meyer G., Smith K., Caldwell J., Furst D.E.: Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. Pharmacogenetics, 2004; 14: 733-739. (Pubitemid 39552788)
19. Drozdzik M., Rudas T., Pawlik A., Gornik W., Kurzawski M., Herczynska M.: Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis. Pharmacogenomics J., 2007; 7: 404-407. (Pubitemid 350192886)
20. Galpin A.J., Schuetz J.D., Masson E., Yanishevski Y., Synold T.W., Barredo J.C., Pui C.H., Relling M.V., Evans W.E.: Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity. Mol. Pharmacol., 1997; 52: 155-163. (Pubitemid 27318631)
21. Ghodke Y., Chopra A., Joshi K., Patwardhan B.: Are thymidylate synthase and methylene tetrahydrofolate reductase genes linked with methotrexate response (efficacy, toxicity) in Indian (Asian) rheumatoid arthritis patients? Clin. Rheumatol., 2008; 27: 787-789.
22. Goto Y., Yue L., Yokoi A., Uehara T., Koizumi S., Saikawa Y.: A novel single-nucleotide polymorphism in the 3'-untranslated region of the human dihydrofolate reductase gene with enhanced expression. Clin. Cancer Res., 2001; 7: 1952-1956. (Pubitemid 32994830)
23. Gusella M., Padrini R.: G>C SNP of thymidylate synthase with respect to colorectal cancer. Pharmacogenomics, 2007; 8: 985-996. (Pubitemid 47423688)
24. Hayashi H., Fujimaki C., Inoue K., Suzuki T., Itoh K.: Genetic polymorphism of C452T (T127I) in human gamma-glutamyl hydrolase in a Japanese population. Biol. Pharm. Bull., 2007; 30: 839-841. (Pubitemid 46571013)
25. Heil S.G., Van der Put N.M., Waas E.T., den Heijer M., Trijbels F.J., Blom H.J.: Is mutated serine hydroxymethyltransferase (SHMT) involved in the etiology of neural tube defects? Mol. Genet. Metab., 2001; 73: 164-172. (Pubitemid 32550154)
26. Herrlinger K.R., Cummings J.R., Barnardo M.C., Schwab M., Ahmad T., Jewell D.P.: The pharmacogenetics of methotrexate in inflammatory bowel disease. Pharmacogenet. Genomics, 2005; 15: 705-711. (Pubitemid 41345322)
27. Hider S.L., Mack L.F., Armstrong D.J., Shadforth M.F., Bruce I.N., Thomson W.: Single nucleotide polymorphisms within adenosine receptor A2a are associated with gastrointestinal (GI) adverse events on MTX therapy. Rheumatology, 2006, 45: i104.
28. Hoffmeyer S., Burk O., von Richter O., Arnold H.P., Brockmöller J., Johne A., Cascorbi I., Gerloff T., Roots I., Eichelbaum M., Brinkmann U.: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA, 2000; 97: 3473-3478. (Pubitemid 30183327)
29. Hol F.A., van der Put N.M., Geurds M.P., Heil S.G., Trijbels F.J., Harnel B.C., Mariman E.C., Blom H.J.: Molecular genetic analysis of the gene encoding the trifunctional enzyme MTHFD (methylenetetrahydrofolate-dehydrogenase, methenyltetrahydrofolate-cyclohydrolase, formyltetrahydrofolate synthetase) in patients with neural tube defects. Clin. Genet., 1998; 53: 119-125. (Pubitemid 28188213)
30. Inoue S., Hashiguchi M., Chiyoda T., Sunami Y., Tanaka T., Mochizuki M.: Pharmacogenetic study of methylenetetrahydrofolate reductase and thymidylate synthase in Japanese and assessment of ethnic and gender differences. Pharmacogenomics, 2007; 8: 41-47. (Pubitemid 46157756)
31. James H.M., Gillis D., Hissaria P., Lester S., Somogyi A.A., Cleland L.G., Proudman S.M.: Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis. J. Rheumatol., 2008; 35: 562-571. (Pubitemid 351500050)
32. Kawakami K., Watanabe G.: Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res., 2003; 15: 6004-6007. (Pubitemid 37187503)
33. Krajinovic M.: MTHFD1 gene: role in disease susceptibility and pharmacogenetics. Pharmacogenomics, 2008; 9: 829-832.
34. Krajinovic M., Lemieux-Blanchard E., Chiasson S., Primeau M., Costea I., Moghrabi A.: Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia. Pharmacogenomics J., 2004; 4: 66-72. (Pubitemid 38256607)
35. Kumagai K., Hiyama K., Oyama T., Maeda H., Kohno N.: Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. Int. J. Mol. Med., 2003; 11: 593-600.
36. Laverdiere C., Chiasson S., Costea I., Moghrabi A., Krajinovic M.: Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood, 2002; 100: 3832-3834. (Pubitemid 35303961)
37. Li W.W., Waltham M., Tong W., Schweitzer B.I., Bertino J.R.: Increased activity of gamma-glutamyl hydrolase in human sarcoma cell lines: a novel mechanism of intrinsic resistance to methotrexate (MTX). Adv. Exp. Med. Biol., 1993; 338: 635-638. (Pubitemid 23340667)
38. Longo G.S., Gorlick R., Tong W.P., Ercikan E., Bertino J.R.: Disparate affinities of antifolates for folylpolyglutamate synthetase from human leukemia cells. Blood, 1997; 90: 1241-1245. (Pubitemid 27314162)
39. Luo H.R., Lü X.M., Yao Y.G., Horie N., Takeishi K., Jorde L.B., Zhang Y.P.: Length polymorphism of thymidylate synthase regulatory region in Chinese populations and evolution of the novel alleles. Biochem. Genet., 2002; 40: 41-51. (Pubitemid 34407095)
40. Marsh S.: Thymidylate synthase pharmacogenetics. Invest. New Drugs, 2005; 23: 533-537. (Pubitemid 43162472)
41. Marsh S., McKay J.A., Cassidy J., McLeod H.L.: Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int. J. Oncol., 2001; 19: 383-386.
42. Merkelbach-Bruse S., Hans V., Mathiak M., Sanguedolce R., Alessandro R., Rüschoff J., Büttner R., Houshdaran F., Gullotti L.: Associations between polymorphisms in the thymidylate synthase gene, the expression of thymidylate synthase mRNA and the microsatellite instability phenotype of colorectal cancer. Oncol. Rep., 2004; 11: 839-843.
43. Montesinos M.C., Takedachi M., Thompson L.F., Wilder T.F., Fernández P., Cronstein B.N.: The antiinflammatory mechanism of methotrexate depends on extracellular conversion of adenine nucleotides to adenosine by ecto-5'-nucleotidase: findings in a study of ec-to-5'-nucleotidase gene-deficient mice. Arthritis Rheum., 2007; 56: 1440-1445. (Pubitemid 46764071)
44. Nakashima-Matsushita N., Homma T., Yu S., Matsuda T., Sunahara N., Nakamura T., Tsukano M., Ratnam M., Matsuyama T.: Selective expression of folate receptor beta and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis Rheum., 1999; 42: 1609-1616. (Pubitemid 30263627)
45. Panetta J.C., Wall A., Pui C.H., Relling M.V., Evans W.E.: Methotrexate intracellular disposition in acute lymphoblastic leukemia: a mathematical model of gamma-glutamyl hydrolase activity. Clin. Cancer Res., 2002; 8: 2423-2429. (Pubitemid 34753618)
46. Pawlik A., Baskiewicz-Masiuk M., Machalinski B., Kurzawski M., Gawronska-Szklarz B.: Involvement of C3435T and G2677T multidrug resistance gene polymorphisms in release of cytokines from peripheral blood mononuclear cells treated with methotrexate and de-xamethasone. Eur. J. Pharmacol., 2005, 28: 27-36. (Pubitemid 41773648)
47. Ranganathan P., Culverhouse R., Marsh S., Mody A., Scott-Horton T.J., Brasington R., Joseph A., Reddy V., Eisen S., McLeod H.L.: Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J. Rheumatol., 2008; 35: 572-579. (Pubitemid 351500051)
48. Rhee M.S., Wang Y., Nair M.G., Galivan J.: Acquisition of resistance to antifolates caused by enhanced gamma-glutamyl hydrolase activity. Cancer Res., 1993; 15: 2227-2230. (Pubitemid 23156804)
49. Rothem L., Ifergan I., Kaufman Y., Priest D.G., Jansen G., Assaraf Y.G.: Resistance to multiple novel antifolates is mediated via defective drug transport resulting from clustered mutations in the reduced folate carrier gene in human leukaemia cell lines. Biochem. J., 2002; 367: 741-750. (Pubitemid 35305713)
50. Rots M.G., Pieters R., Peters G.J., Noordhuis P., van Zantwijk C.H., Kaspers G.J., Hählen K., Creutzig U., Veerman A.J., Jansen G.: Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia. Blood, 1999; 93: 1677-1683. (Pubitemid 29102496)
51. Saag K.G., Teng G.G., Patkar N.M., Anuntiyo J., Finney C., Curtis J.R., Paulus H.E., Mudano A., Pisu M., Elkins-Melton M., Outman R., Allison J.J., Suarez Almazor M., Bridges S.L. Jr, Chatham W.W., Hochberg M., MacLean C., Mikuls T., Moreland L.W., O'Dell J., Turkiewicz A.M., Furst D.E., American College of Rheumatology: American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum., 2008; 59: 762-784. (Pubitemid 351847559)
52. Schneider E., Ryan T.J.: Gamma-glutamyl hydrolase and drug resistance. Clin. Chim. Acta, 2006; 374: 25-32. (Pubitemid 44574494)
53. Sharma S., Das M., Kumar A., Marwaha V., Shankar S., Aneja R., Grover R., Arya V., Dhir V., Gupta R., Kumar U., Juyal R.C.: Interaction of genes from influx-metabolism-efflux pathway and their influence on methotrexate efficacy in rheumatoid arthritis patients among Indians. Pharmacogenet. Genomics., 2008; 18: 1041-1049.
54. Stamp L., Roberts R., Kennedy M., Barclay M., O'Donnell J., Chapman P.: The use of low dose methotrexate in rheumatoid arthritis - are we entering a new era of therapeutic drug monitoring and pharmacogenomics? Biomed. Pharmacother., 2006; 60: 678-687. (Pubitemid 44821708)
55. Stranzl T., Wolf J., Leeb B.F., Smolen J.S., Pirker R., Filipits M.: Expression of folylpolyglutamyl synthetase predicts poor response to methotrexate therapy in patients with rheumatoid arthritis. Clin. Exp. Rheumatol., 2003; 2: 27-32. (Pubitemid 36267528)
56. Świerkot J., Ślezak R., Karpinski P., Pawlowska J., Noga L.: Is toxicity of methotrexate in rheumatoid arthritis associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes? Ann. Rheum. Dis., 2009; 68(Suppl. 3): 588.
57. Takatori R., Takahashi K.A., Tokunaga D., Hojo T., Fujioka M., Asano T., Hirata T., Kawahito Y., Satomi Y., Nishino H., Tanaka T., Hirota Y., Kubo T.: ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients. Clin. Exp. Rheumatol., 2006; 24: 546-554. (Pubitemid 44911249)
58. Trinh B.N., Ong C.N., Coetzee G.A., Yu M.C., Laird P.W.: Thymidylate synthase: a novel genetic determinant of plasma homocysteine and folate levels. Hum. Genet., 2002; 111: 299-302. (Pubitemid 36075054)
59. Ulrich C.M., Bigler J., Velicer C.M., Greene E.A., Farin F.M., Potter J.D.: Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol. Biomarkers Prev., 2000; 9: 1381-1385. (Pubitemid 32044809)
60. van der Straaten R., Wessels J.A., de Vries-Bouwstra J.K.: Exploratory analysis of four polymorphisms in human GGH and FPGS genes and their effect in methotrexate-treated rheumatoid arthritis patients. Pharmacogenomics, 2007; 8: 141-150.
61. van Ede A.E., Laan R.F., Blom H.J., De Abreu R.A., van de Putte L.B.: Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin. Arthritis Rheum., 1998; 27: 277-292. (Pubitemid 28176234)
62. Visser K., Katchamart W., Loza E., Martinez-Lopez J.A., Salliot C., Trudeau J., Bombardier C., Carmona L., van der Heijde D., Bijlsma J.W., Boumpas D.T., Canhao H., Edwards C.J., Hamuryudan V., Kvien T.K., Leeb B.F., Martín-Mola E.M., Mielants H., Müller-Ladner U., Murphy G., Ostergaard M., Pereira I.A., Ramos-Remus C., Valentini G., Zochling J., Dougados M.: Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann. Rheum. Dis., 2009; 68: 1086-1093.
63. Volk E.L., Farley K.M., Wu Y., Li F., Robey R.W., Schneider E.: Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res., 2002; 62: 5035-5040. (Pubitemid 34984431)
64. Warren R.B., Smith R.L., Campalani E., Eyre S., Smith C.H., Barker J.N., Worthington J., Griffiths C.E.: Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms. Br. J. Dermatol., 2009; 160: 438-441.
65. Weisman M.H., Furst D.E., Park G.S., Kremer J.M., Smith K.M., Wallace D.J., Caldwell J.R., Dervieux T.: Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis. Arthritis Rheum., 2006; 54: 607-612. (Pubitemid 43228638)
66. Wessels J.A., de Vries-Bouwstra J.K., Heijmans B.T., Slagboom P.E., Goekoop-Ruiterman Y.P., Allaart C.F., Kerstens P.J., van Zeben D., Breedveld F.C., Dijkmans B.A., Huizinga T.W., Guchelaar H.J.: Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum., 2006; 54: 1087-1095. (Pubitemid 43672921)
67. Wessels J.A., Kooloos W.M., De Jonge R., De Vries-Bouwstra J.K., Allaart C.F., Linssen A., Collee G., De Sonnaville P., Lindemans J., Huizinga T.W., Guchelaar H.J.: Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis Rheum. 2006; 54: 2830-2839. (Pubitemid 44497761)
68. Whetstine J.R., Witt T.L., Matherly L.H.: The human reduced folate carrier gene is regulated by the AP2 and sp1 transcription factor families and a functional 61-base pair polymorphism. J. Biol. Chem., 2002; 277: 43873-43880. (Pubitemid 36157810)
69. Yawata A., Kim S.R., Miyajima A., Kubo T., Ishida S., Saito Y., Nakajima Y., Katori N., Matsumoto Y., Fukuoka M., Ohno Y., Ozawa S., Sawada J.: Polymorphic tandem repeat sequences of the thymidylate synthase gene correlates with cellular-based sensitivity to fluoro-pyrimidine antitumor agents. Cancer Chemother. Pharmacol., 2005; 56: 465-472. (Pubitemid 41549147)
70. Zeng Q.Y., Wang Y.K., Xiao Z.Y., Chen S.B.: Pharmacogenetic study of 5, 10-methylenetetrahydrofolate reductase C677T and thymidylate synthase 3R/2R gene polymorphisms and methotrexate-related toxicity in Chinese Han patients with inflammatory arthritis. Ann. Rheum. Dis., 2008; 67: 1193-1194.